[Contribution of experimental models to the treatment of respiratory tract infections]
Related Experiment Videos
C Chidiac1, S Nelson, W R Summer
1Service Régional des Maladies Infectieuses et Tropicales, Centre Hospitalier de Tourcoing, France.
Abstract:
The need for more effective and potentially less toxic antimicrobial agents than aminoglycosides for treatment of gram negative bacilli pneumonia specially Pseudomonas aeruginosa, explains the interest for experimental models of pneumonia. These models allow to study the efficacy and safety of antibiotics alone or in combination. Aminoglycosides and new quinolones are more effective than beta-lactams for life threatening infection with high inoculum, the only exception to this finding has been for N-formimidoyl thienamycin, whereas for less severe infections aminoglycosides and beta-lactams are equivalent in efficacy. In contrast to high inocula pneumonia, combining beta-lactams with aminoglycosides give additive of synergic benefits for treating low inocula. Experimental models allow to compare continuous versus intermittent administration of antibiotics, different regimens of the same antibiotics (single daily dose of aminoglycosides versus conventional administration) and new antiinfectious agents as anti-pseudomonas hyperimmune globulins.
Insights
Experimental pneumonia models are crucial for evaluating novel antimicrobial agents against gram-negative bacilli, particularly Pseudomonas aeruginosa. Research focuses on finding safer, more effective treatments than current options like aminoglycosides.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Context:
- Gram-negative bacilli pneumonia, especially caused by Pseudomonas aeruginosa, necessitates improved antimicrobial therapies.
- Aminoglycosides are a standard treatment but have toxicity concerns.
- Experimental pneumonia models are vital for assessing antibiotic efficacy and safety.
Purpose:
- To investigate the efficacy and safety of various antimicrobial agents and administration strategies for pneumonia.
- To compare the effectiveness of different antibiotic classes (aminoglycosides, quinolones, beta-lactams) against gram-negative bacilli.
- To explore novel therapeutic approaches, including antibiotic combinations and hyperimmune globulins.
Summary:
- Experimental models demonstrate that aminoglycosides and new quinolones are superior to beta-lactams for high-inoculum pneumonia, except for N-formimidoyl thienamycin.
- For less severe infections, aminoglycosides and beta-lactams show equivalent efficacy.
- Combining beta-lactams with aminoglycosides offers synergistic benefits for low-inoculum pneumonia, unlike in high-inoculum scenarios.
Impact:
- Provides insights into optimizing antibiotic regimens for gram-negative pneumonia.
- Facilitates the development of less toxic and more effective antimicrobial treatments.
- Supports comparative studies of continuous versus intermittent antibiotic administration and novel agents like hyperimmune globulins.